Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    MACULAR DEGENERATION, AGE-RELATED, 6
Show Display Options
Rank Status Study
1 Terminated Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Condition: Age-related Macular Degeneration
Intervention:
2 Completed Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Conditions: Age-Related Maculopathy;   Age-Related Maculopathies;   Eye Diseases;   Retinal Degeneration;   Macular Degeneration
Interventions: Biological: RN6G;   Biological: Placebo
3 Completed
Has Results
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
Conditions: Age-Related Maculopathy;   Age-Related Maculopathies;   Eye Diseases;   Retinal Degeneration;   Macular Degeneration
Interventions: Biological: RN6G;   Biological: Placebo
4 Unknown  A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Condition: Age-Related Macular Degeneration (AMD)
Intervention: Drug: pegaptanib sodium (Macugen)
5 Terminated
Has Results
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
Condition: Age-Related Maculopathy
Interventions: Biological: RN6G;   Biological: Placebo
6 Completed Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
Condition: Wet Age-Related Macular Degeneration
Intervention: Drug: ACZ885
7 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
8 Completed Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium
9 Terminated Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Interventions: Drug: Photodynamic Therapy (PDT) with Visudyne (verteporfin);   Drug: Macugen (pegaptanib sodium)
10 Completed Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL;   Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL;   Other: Anecortave Acetate Vehicle
11 Terminated A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: Pegaptanib sodium
12 Completed
Has Results
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
13 Completed A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Condition: Age-Related Macular Degeneration
Intervention: Drug: Pegaptanib sodium
14 Active, not recruiting Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
Condition: Neovascular Age-Related Macular Degeneration
Interventions: Drug: RTH258 solution for IVT injection;   Drug: Aflibercept solution for IVT injection
15 Completed Phase II/III Study of Anti-VEGF in Neovascular AMD
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Drug: EYE001 anti-VEGF aptamer
16 Recruiting Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
Conditions: Age-Related Macular Degeneration;   Retinal Vein Occlusion;   Diabetic Macular Edema
Intervention: Drug: pegaptanib sodium injection
17 Recruiting Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
Condition: Visual Impairment Due to Neovascular AMD
Interventions: Drug: Ranibizumab;   Drug: Aflibercept
18 Completed Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula
Condition: Diabetic Macular Edema
Intervention: Drug: pegaptanib sodium (Macugen)
19 Completed
Has Results
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
Condition: Macular Edema Associated With Diabetes Mellitus
Interventions: Drug: Standard of Care;   Drug: Macugen
20 Withdrawn Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: EBI-031

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.